title: New perspectives in managing myeloproliferative disorders: focus on the patient.
abstract: Risk stratification is the basis for treatment decisions in the chronic myeloproliferative disorders, and in addition to the three established risk factors of previous thrombosis, age and platelets >1500 x 10(9), cardiovascular risk factors should be addressed. In addition, premorbidity with regard to possible side effects of platelet-reducing drugs as well as the impact on quality of life of such side effects should be considered. The near-to-normal life expectancy and long term nature of treatment also makes it necessary to consider the potential leukaemogenic effects of some cytostatic drugs.
authors.affiliation: Department of Haematology, University Hospital, Uppsala, Sweden. gunnar.birgegard@medsci.uu.se
authors.forename: Gunnar
authors.initials: G
authors.lastname: Birgegård
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019468:Disease Management; D006801:Humans; D009196:Myeloproliferative Disorders / Q000175:diagnosis* / Q000188:drug therapy*; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents